Free tool
FAERS Monitor: Anzupgo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219155 or its brand name (Anzupgo, Delgocitinib). Reports on generic versions are filed under their own applications.
Reports
269
Serious
85
32% of reports
Hospitalization
38
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product use in unapproved indication58
- pruritus30
- dermatitis atopic25
- drug ineffective22
- dermatitis21
- erythema20
- rash17
- burning sensation13
- dry skin13
- eczema13
- skin burning sensation10
- skin exfoliation10
- off label use9
- erythema multiforme8
- condition aggravated6
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 7 |
| 2023 | 8 |
| 2024 | 14 |
| 2025 | 89 |
| 2026 | 145 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,890 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dermatitisSignal | 21 | 78.4 | 52.0 | 1,529 |
| erythema multiformeSignal | 8 | 67.1 | 33.9 | 457 |
| dermatitis atopicSignal | 25 | 37.1 | 25.5 | 844 |
| eczemaSignal | 13 | 19.4 | 11.4 | 210 |
| product use in unapproved indicationSignal | 58 | 18.3 | 14.6 | 942 |
| burning sensationSignal | 13 | 14.5 | 8.5 | 151 |
| skin burning sensationSignal | 10 | 10.9 | 5.9 | 81 |
| skin exfoliationSignal | 10 | 9.3 | 5.0 | 66 |
| dry skinSignal | 13 | 7.6 | 4.5 | 69 |
| erythemaSignal | 20 | 7.6 | 5.0 | 109 |
| pruritusSignal | 30 | 6.1 | 4.4 | 125 |
| rashSignal | 17 | 3.0 | 1.9 | 22 |
| condition aggravated | 6 | 1.5 | 0.7 | 1 |
| drug ineffective | 22 | 1.3 | 0.9 | 1 |
| off label use | 9 | 0.8 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.